Clinical Utility of Procalcitonin for Stratifying Severity in Sepsis Secondary to Pneumonia

Wachyoe Hadi Saputra; Agus Prima; Wirdah Wirdah

doi:10.71197/jsocmed.v5i1.253

Clinical Utility of Procalcitonin for Stratifying Severity in Sepsis Secondary to Pneumonia

Wachyoe Hadi Saputra
Ibnu Sina Hospital, Aceh, Indonesia
Agus Prima
Division of Anesthesiology and Intensive Care, National Center of Research and Education Institute (NCREI), Medan, Indonesia
Wirdah Wirdah
Ibnu Sina Hospital, Aceh, Indonesia

Abstract

Introduction: Procalcitonin (PCT) is a biomarker that reflects the systemic inflammatory response to bacterial infections and has been widely studied in the context of sepsis. In patients with pneumonia, early identification of the severity of sepsis is essential for appropriate clinical management and prognostic evaluation. This study aimed to assess the clinical utility of serum procalcitonin levels in stratifying sepsis severity in patients with pneumonia.

Methods: This analytical cross-sectional study was conducted between February 2013 and March 2014 in the Emergency Department and Internal Medicine Wards of Dr. Zainoel Abidin General Hospital in Banda Aceh, Indonesia. Thirty patients diagnosed with pneumonia were enrolled in this study using quota sampling method. Serum procalcitonin levels were measured and categorized according to the severity of sepsis. Statistical analysis was performed using one-way analysis of variance (ANOVA), followed by the least significant difference (LSD) post-hoc test using the SPSS software. Statistical significance was set at P < 0.05.

Results: Serum procalcitonin levels progressively increased with increasing severity of sepsis. The lowest PCT level was observed in patients with pneumonia without sepsis (0.091 ng/mL), followed by those with sepsis (0.686 ng/mL), severe sepsis (3.593 ng/mL), and septic shock (21.703 ng/mL). Significant differences in PCT levels were found across the severity groups (P < 0.05), indicating a strong relationship between elevated procalcitonin levels and worsening clinical severity.

Conclusion: Serum procalcitonin levels correlate with the severity of sepsis in patients with pneumonia and may serve as a useful biomarker for sepsis severity stratification and clinical risk assessment.

Similar Articles

Jonathan Junius Sibarani, Oryza Satria, Dina Aprilya, Minimally Invasive Correction of Proximal Phalanx Malunion Using Cannulated Headless Screws: A Case Series , Journal of Society Medicine: Vol. 4 No. 10 (2025): October

<< < 5 6 7 8 9 10

You may also start an advanced similarity search for this article.

PDF

Published at

31. January 2026
https://doi.org/10.71197/jsocmed.v5i1.253
Issue:

Vol. 5 No. 1 (2026): January
Section:

Review Articles
Keywords:

Procalcitonin Sepsis Severity Pneumonia Biomarkers Systemic Infection Septic Shock
References:

Nasronudin. Imunopatogenesis sepsis dan prinsip penatalaksanaan. Penyakit Infeksi di Indonesia. Surabaya: Airlangga University Press. 2007;1(1):238-245.

Martin GS, Mannino DM. Epidemiology of sepsis in the United States from 1979 to 2000. N Engl J Med. 2003;348(16):1546-1554.

Müller-Redetzky H, Suttorp N, Witzenrath M. Experimental models of pneumonia-induced sepsis. Drug Discov Today Dis Model. 2012;9(1):23-32.

Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, et al. Epidemiology of sepsis in Germany: results of a national prospective multicenter study. Intensive Care Med. 2007;33(4):606-618.

Giamarellos-Bourboulis EJ, Tsangaris I, Kanni T, Mouktaroudi M, Pantelidou I, Adamis G, et al. Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect. 2011;77(1):58-63.

Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and therapeutic target. Br J Pharmacol. 2010;159(2):253-264.

Kopterides P, Tsangaris I. Procalcitonin and sepsis: recent data on diagnostic utility, prognostic potential and therapeutic implications in critically ill patients. Minerva Anestesiol. 2012;78(7):823-835.

Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002;323(1–2):17-29.

Ugarte H, Silva E, Mercan D, Mendonça AD, Vincent JL. Procalcitonin is used as a marker of infection in the intensive care unit. Crit Care Med. 1999;27(3):498-504.

Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7(3):210-217.

Azkárate I, Choperena G, Salas E, Sebastián R, Lara G, Elósegui I, et al. Epidemiology and prognostic factors of severe sepsis and septic shock: evolution over six years. Med Intensiva. 2016;40(1):18-25.

Sims CR, Nguyen TC, Mayeux PR. Can biomarkers direct therapy for patients with sepsis? J Pharmacol Exp Ther. 2016;357(2):228-239.

Sign C. Diagnosis of pneumonia in adults in general practice. Scand J Prim Health Care. 1992;10(4):226-233.

Melbye H, Straume B, Aasebø U, Brox J. Diagnosis of adult pneumonia in general practice. Scand J Prim Health Care. 1988;6(2):111-117.

Hammer C, Hobel G, Hamme S. Diagnosis and monitoring of inflammatory events in transplant patients. In: Trull AK, Demers LM, Holt DW, editors. Biomarkers in Disease: An Evidence-Based Approach. Cambridge: Cambridge University Press; 2002;1(1):474-488.

Guntur HA. SIRS, sepsis dan syok septik. Surakarta: Sebelas Maret University Press. 2008;1(1)1-10.

Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250-1256.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. International guidelines for the management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.

Brunkhorst FM, Wegscheider K. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 2000;26(1):148-153.

Harbarth S, Holeckova K, Pittet D, Ricou B, Grau GE, Vadas L, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396-402.

Dorizzi RM, Polati E, Sette P, Ferrari A, Rizzotti P, Luzzani A. Procalcitonin in the diagnosis of inflammation in intensive care units. Clin Biochem. 2006;39(12):1138-1143.

Rau B, Krüger C, Schilling M. Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbecks Arch Surg. 2004;389(2):134-144.

Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med. 2000;26(9):1193-1200.

Abu Elkhashab AE, Swelem RS, Abd Alla AE, Hattata EA, Atta MS. Etiological and prognostic values of procalcitonin in hospital-acquired pneumonia. Egypt J Chest Dis Tuberc. 2014;63(2):201-206.

Balci C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care. 2003;7(1):85-90.

Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D, Sgarbi L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care. 2004;8(4):234-242.

Jeong S, Park Y, Cho Y, and Kim HS. Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture. Clin Chim Acta. 2012;413(19-20):1731-1736.

Köszegi T. Immunoluminometric detection of human procalcitonin. J Biochem. Biophys. Methods 2002;53(1-3):157-164.

Sibila O, Meduri GU, Mortensen EM, Anzueto A, Laserna E, Fernandez JF, et al. Improving the 2007 IDSA/ATS severe community-acquired pneumonia criteria to predict intensive care unit admission. J Crit Care. 2013;28(3):284-290.
Share:

Z

Saputra , W. H., Prima, A., & Wirdah, W. (2026). Clinical Utility of Procalcitonin for Stratifying Severity in Sepsis Secondary to Pneumonia. Journal of Society Medicine, 5(1), 31–38. https://doi.org/10.71197/jsocmed.v5i1.253